Medicinal Chemistry Research Laboratory for Medium Molecular Drug Discovery, Shionogi and Co., Ltd., Osaka, Japan.
Nucleic Acid Ther. 2019 Feb;29(1):44-50. doi: 10.1089/nat.2018.0741. Epub 2018 Dec 1.
Antisense oligonucleotides (ASOs) are classified into gapmer and non-gapmer types according to their chemical modification pattern and mechanism of action. Although gapmer ASOs effectively reduce target RNA expression through intracellular RNase H1, high-affinity gapmer ASOs also have hepatotoxic potential. Non-gapmer ASOs, which are mainly used for pre-mRNA splicing regulation or functional inhibition of microRNA through their steric effects, are also able to inhibit target RNA expression using nonsense-mediated decay. However, it was unknown if they induce high knockdown activity without showing hepatotoxicity. In this study, we investigated the modification pattern of non-gapmer ASOs and show that they have comparable knockdown potential if they have an appropriate melting temperature (T) range. We also demonstrated that non-gapmer ASOs show high knockdown effects without inducing hepatotoxicity in the mouse liver. These results indicated that non-gapmer ASOs have the potential to become an alternative inhibitor of target expression with a lower risk of hepatotoxicity.
反义寡核苷酸(ASOs)根据其化学修饰模式和作用机制分为 Gapmer 和非 Gapmer 两种类型。虽然 Gapmer ASOs 通过细胞内 RNase H1 有效降低靶 RNA 的表达,但高亲和力的 Gapmer ASOs 也具有潜在的肝毒性。非 Gapmer ASOs 主要通过其空间位阻效应来调节前体 mRNA 的剪接或抑制 microRNA 的功能,也能够通过无意义介导的衰变抑制靶 RNA 的表达。然而,目前尚不清楚它们在不表现出肝毒性的情况下是否具有高敲低活性。在这项研究中,我们研究了非 Gapmer ASOs 的修饰模式,并表明如果它们具有适当的融解温度(T)范围,则具有相当的敲低潜力。我们还证明,非 Gapmer ASOs 具有很高的敲低效果,而不会在小鼠肝脏中引起肝毒性。这些结果表明,非 Gapmer ASOs 有可能成为一种具有较低肝毒性风险的靶表达替代抑制剂。